MADRID, December 26 (EUROPA PRESS) –
Scientists at Northwestern Medicine have discovered two therapies that, tested in mice, can slow the progression of pediatric leukemia, so they now hope to combine them into a super drug. and test it on people in the context of a clinical trial.
Although there are several types of leukemia, this research, which was published in three studies in the last two years in the journal Cell, and in a final article in Genes & Development, two most common in infants through adolescents: acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL).
In the last 25 years, the Shilatifard laboratory has been studying the molecular function of the key protein of leukemia, called MLL, within its complex known as COMPASS (complex proteins associated with Set1), which has been seen as one of the mutations identified with more often in cancer.
"I have been working on this translocation for over two decades, and finally we are at the point where, in five or ten years from now, we can get a medication for children that can be effective if we can increase that survival rate by 85%. , this is a great achievement, "the researchers said.